Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
The case alleges Capricor Therapeutics and certain of its top executives made false and/or misleading statements to investors.
-
Capricor Therapeutics Hit with Securities Fraud Investigation over Clinical Data Misrepresentations – Investors Urged to Contact BFA Law
-
Suffer Losses on Your Capricor Therapeutics Investment? BFA Law Notifies Investors of the Securities Fraud Lawsuit to Recover Losses
-
Deborah Ascheim, M.D., former Capricor Therapeutics CMO, elected to stem cell therapy company Longeveron (LGVN) Board of Directors.
-
NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Capricor Therapeutics, Inc. (NASDAQ: CAPR)...
-
The suit claims Capricor misled investors on its DMD drug deramiocel; FDA denied its BLA, citing lack of evidence, causing shares to fall.
-
Defendants allegedly misled investors on deramiocel’s FDA approval prospects; after a CRL denial, Capricor’s stock fell nearly 33%.
-
The complaint alleges Capricor misled investors on deramiocel’s trial data and BLA prospects, concealing risks that led to FDA’s rejection.
-
If you purchased or acquired securities in any of the above companies during their class period and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or...
-
If you purchased or acquired securities in any of the above companies during their class period and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or...